Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI4736 plus tremelimumab in advanced solid tumors
NL-OMON47386Phase 1Recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2016
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of durvalumab and tremelimumab in Nonhematologic neoplasms, transitional cell carcinoma (TCC), small cell lung cancer (SCLC) and 5 more (3 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability, Maximum tolerated dose or highest protocol-defined dose and 1 more. Started Dec 2016; status: recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
Nonhematologic neoplasmstransitional cell carcinoma (TCC)small cell lung cancer (SCLC)soft tissue sarcoma (STS)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NL-OMON47386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47386.